Appendix 4G

Key to Disclosures Corporate Governance Council Principles and Recommendations

Name of entity		
Medibio Limit	ed	
ABN/ARBN 58 008 130 33	6	Financial year ended 30 June 2016
Our corporate go	vernance statement ²	or the above period above can be found at: ³
	of our annual report: RL on our website:	http://www.medibio.com.au/index.php/about/corporate-governance
The Corporate Gothe board.	overnance Statement	s accurate and up to date as at 30 June 2016 and has been approved by
The annexure inc	ludes a key to where	our corporate governance disclosures can be located.
Date here:	30 September 2016	
Sign here:	Company Secretary	△
Print name:	Robert Lees	

¹ Under Listing Rule 4.7.3, an entity must lodge with ASX a completed Appendix 4G at the same time as it lodges its annual report with ASX.

Listing Rule 4.10.3 requires an entity that is included in the official list as an ASX Listing to include in its annual report either a corporate governance statement that meets the requirements of that rule or the URL of the page on its website where such a statement is located. The corporate governance statement must disclose the extent to which the entity has followed the recommendations set by the ASX Corporate Governance Council during the reporting period. If the entity has not followed a recommendation for any part of the reporting period, its corporate governance statement must separately identify that recommendation and the period during which it was not followed and state its reasons for not following the recommendation and what (if any) alternative governance practices it adopted in lieu of the recommendation during that period.

Under Listing Rule 4.7.4, if an entity chooses to include its corporate governance statement on its website rather than in its annual report, it must lodge a copy of the corporate governance statement with ASX at the same time as it lodges its annual report with ASX. The corporate governance statement must be current as at the effective date specified in that statement for the purposes of rule 4.10.3.

1

² "Corporate governance statement" is defined in Listing Rule 19.12 to mean the statement referred to in Listing Rule 4.10.3 which discloses the extent to which an entity has followed the recommendations set by the ASX Corporate Governance Council during a particular reporting period.

³ Mark whichever option is correct and then complete the page number(s) of the annual report, or the URL of the web page, where the entity's corporate governance statement can be found.

ANNEXURE – KEY TO CORPORATE GOVERNANCE DISCLOSURES

Corpo	rate Governance Council recommendation	We have followed the recommendation in full for the whole of the period above. We have disclosed	We have <u>NOT</u> followed the recommendation in full for the whole of the period above. We have disclosed
PRIN	CIPLE 1 – LAY SOLID FOUNDATIONS FOR MANAGE	EMENT AND OVERSIGHT	
1.1	A listed entity should disclose: (a) the respective roles and responsibilities of its board and management; and (b) those matters expressly reserved to the board and those delegated to management.	the fact that we follow this recommendation: in our Corporate Governance Statement OR at this location: Insert location here and information about the respective roles and responsibilities of our board and management (including those matters expressly reserved to the board and those delegated to management): at this location: http://www.medibio.com.au/index.php/about/corporate-governance Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable
1.2	A listed entity should: (a) undertake appropriate checks before appointing a person, or putting forward to security holders a candidate for election, as a director; and (b) provide security holders with all material information in its possession relevant to a decision on whether or not to elect or re-elect a director. A listed entity should have a written agreement with each director and senior executive setting out the terms of their appointment.	the fact that we follow this recommendation: in our Corporate Governance Statement OR at this location: _ http://www.medibio.com.au/index.php/about/corporate-governance	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable
		Insert location here	

Corporate Governance Council recommendation		We have followed the recommendation in full for the whole of the period above. We have disclosed	We have <u>NOT</u> followed the recommendation in full for the whole of the period above. We have disclosed
1.4	The company secretary of a listed entity should be accountable directly to the board, through the chair, on all matters to do with the proper functioning of the board.	the fact that we follow this recommendation: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable
1.5	A listed entity should: (a) have a diversity policy which includes requirements for the board or a relevant committee of the board to set measurable objectives for achieving gender diversity and to assess annually both the objectives and the entity's progress in achieving them; (b) disclose that policy or a summary of it; and (c) disclose as at the end of each reporting period the measurable objectives for achieving gender diversity set by the board or a relevant committee of the board in accordance with the entity's diversity policy and its progress towards achieving them and either: (1) the respective proportions of men and women on the board, in senior executive positions and across the whole organisation (including how the entity has defined "senior executive" for these purposes); or (2) if the entity is a "relevant employer" under the Workplace Gender Equality Act, the entity's most recent "Gender Equality Indicators", as defined in and published under that Act.	the fact that we have a diversity policy that complies with paragraph (a): in our Corporate Governance Statement OR at this location: and a copy of our diversity policy or a summary of it: at this location: http://www.medibio.com.au/index.php/about/corporate-governance the measurable objectives for achieving gender diversity set by the board or a relevant committee of the board in accordance with our diversity policy and our progress towards achieving them: in our Corporate Governance Statement OR at this location: Insert location here at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable

Corporate Governance Council recommendation		We have followed the recommendation in full for the whole of the period above. We have disclosed	We have <u>NOT</u> followed the recommendation in full for the whole of the period above. We have disclosed
1.6	A listed entity should: (a) have and disclose a process for periodically evaluating the performance of the board, its committees and individual directors; and (b) disclose, in relation to each reporting period, whether a performance evaluation was undertaken in the reporting period in accordance with that process.	the evaluation process referred to in paragraph (a): in our Corporate Governance Statement OR at this location: Insert location here and the information referred to in paragraph (b): in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable
1.7	A listed entity should: (a) have and disclose a process for periodically evaluating the performance of its senior executives; and (b) disclose, in relation to each reporting period, whether a performance evaluation was undertaken in the reporting period in accordance with that process.	the evaluation process referred to in paragraph (a): in our Corporate Governance Statement OR at this location: Insert location here and the information referred to in paragraph (b): in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable

Corporate Governance Council recommendation		We have followed the recommendation in full for the whole of the period above. We have disclosed	We have NOT followed the recommendation in full for the whole of the period above. We have disclosed
PRIN	CIPLE 2 - STRUCTURE THE BOARD TO ADD VALUE		
2.1	The board of a listed entity should: (a) have a nomination committee which: (1) has at least three members, a majority of whom are independent directors; and (2) is chaired by an independent director, and disclose: (3) the charter of the committee; (4) the members of the committee; and (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; OR (b) if it does not have a nomination committee, disclose that fact and the processes it employs to address board succession issues and to ensure that the board has the appropriate balance of skills, knowledge, experience, independence and diversity to enable it to discharge its duties and responsibilities effectively.	[If the entity complies with paragraph (a):] the fact that we have a nomination committee that complies with paragraphs (1) and (2): □ at this location: and a copy of the charter of the committee: □ at this location: http://www.medibio.com.au/index.php/about/corporate-governance and the information referred to in paragraphs (4) and (5): □ in our Corporate Governance Statement OR □ at this location: Insert location here [If the entity complies with paragraph (b):] the fact that we do not have a nomination committee and the processes we employ to address board succession issues and to ensure that the board has the appropriate balance of skills, knowledge, experience, independence and diversity to enable it to discharge its duties and responsibilities effectively: □ in our Corporate Governance Statement OR □ at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable
2.2	A listed entity should have and disclose a board skills matrix setting out the mix of skills and diversity that the board currently has or is looking to achieve in its membership.	our board skills matrix: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable

Corporate Governance Council recommendation		We have followed the recommendation in full for the whole of the period above. We have disclosed	We have <u>NOT</u> followed the recommendation in full for the whole of the period above. We have disclosed
2.3	A listed entity should disclose: (a) the names of the directors considered by the board to be independent directors; (b) if a director has an interest, position, association or relationship of the type described in Box 2.3 but the board is of the opinion that it does not compromise the independence of the director, the nature of the interest, position, association or relationship in question and an explanation of why the board is of that opinion; and (c) the length of service of each director.	the names of the directors considered by the board to be independent directors: in our Corporate Governance Statement OR at this location: Insert location here where applicable, the information referred to in paragraph (b): in our Corporate Governance Statement OR at this location: Insert location here the length of service of each director: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement
2.4	A majority of the board of a listed entity should be independent directors.	the fact that we follow this recommendation: i in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement <u>OR</u> we are an externally managed entity and this recommendation is therefore not applicable
2.5	The chair of the board of a listed entity should be an independent director and, in particular, should not be the same person as the CEO of the entity.	the fact that we follow this recommendation: i in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable

±		We have followed the recommendation in full for the whole of the period above. We have disclosed	We have <u>NOT</u> followed the recommendation in full for the whole of the period above. We have disclosed
2.6	A listed entity should have a program for inducting new directors and provide appropriate professional development opportunities for directors to develop and maintain the skills and knowledge needed to perform their role as directors effectively.	the fact that we follow this recommendation: in our Corporate Governance Statement OR at this location:: Insert location here	i an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable
PRIN	CIPLE 3 – ACT ETHICALLY AND RESPONSIBLY		
3.1	A listed entity should: (a) have a code of conduct for its directors, senior executives and employees; and (b) disclose that code or a summary of it.	our code of conduct or a summary of it: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement
PRIN	CIPLE 4 – SAFEGUARD INTEGRITY IN CORPORATE	E REPORTING	
4.1	The board of a listed entity should: (a) have an audit committee which: (1) has at least three members, all of whom are non-executive directors and a majority of whom are independent directors; and (2) is chaired by an independent director, who is not the chair of the board, and disclose: (3) the charter of the committee; (4) the relevant qualifications and experience of the members of the committee; and (5) in relation to each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; OR (b) if it does not have an audit committee, disclose that fact and the processes it employs that independently verify and safeguard the integrity of its corporate reporting, including the processes for the appointment and removal of the external auditor and the rotation of the audit engagement partner.	[If the entity complies with paragraph (a):] the fact that we have an audit committee that complies with paragraphs (1) and (2): ✓ in our Corporate Governance Statement OR at this location: Insert location here and a copy of the charter of the committee: ✓ at this location: http://www.medibio.com.au/index.php/about/corporate-governance	an explanation why that is so in our Corporate Governance Statement

Corpo	rate Governance Council recommendation	We have followed the recommendation in full for the whole of the period above. We have disclosed	We have <u>NOT</u> followed the recommendation in full for the whole of the period above. We have disclosed
		[If the entity complies with paragraph (b):] the fact that we do not have an audit committee and the processes we employ that independently verify and safeguard the integrity of our corporate reporting, including the processes for the appointment and removal of the external auditor and the rotation of the audit engagement partner: in our Corporate Governance Statement OR at this location: Insert location here	
4.2	The board of a listed entity should, before it approves the entity's financial statements for a financial period, receive from its CEO and CFO a declaration that, in their opinion, the financial records of the entity have been properly maintained and that the financial statements comply with the appropriate accounting standards and give a true and fair view of the financial position and performance of the entity and that the opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.	the fact that we follow this recommendation: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement
4.3	A listed entity that has an AGM should ensure that its external auditor attends its AGM and is available to answer questions from security holders relevant to the audit.	the fact that we follow this recommendation: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity that does not hold an annual general meeting and this recommendation is therefore not applicable
PRIN	CIPLE 5 – MAKE TIMELY AND BALANCED DISCLOS	SURE	
5.1	A listed entity should: (a) have a written policy for complying with its continuous disclosure obligations under the Listing Rules; and (b) disclose that policy or a summary of it.	our continuous disclosure compliance policy or a summary of it: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement

Corpo	rate Governance Council recommendation	We have followed the recommendation in full for the whole of the period above. We have disclosed	We have <u>NOT</u> followed the recommendation in full for the whole of the period above. We have disclosed
PRIN	CIPLE 6 – RESPECT THE RIGHTS OF SECURITY HO	LDERS	
6.1	A listed entity should provide information about itself and its governance to investors via its website.	information about us and our governance on our website: at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement
6.2	A listed entity should design and implement an investor relations program to facilitate effective two-way communication with investors.	the fact that we follow this recommendation: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement
6.3	A listed entity should disclose the policies and processes it has in place to facilitate and encourage participation at meetings of security holders.	our policies and processes for facilitating and encouraging participation at meetings of security holders: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity that does not hold periodic meetings of security holders and this recommendation is therefore not applicable
6.4	A listed entity should give security holders the option to receive communications from, and send communications to, the entity and its security registry electronically.	the fact that we follow this recommendation: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement
PRIN	CIPLE 7 – RECOGNISE AND MANAGE RISK		
7.1	The board of a listed entity should: (a) have a committee or committees to oversee risk, each of which: (1) has at least three members, a majority of whom are independent directors; and (2) is chaired by an independent director, and disclose: (3) the charter of the committee; (4) the members of the committee; and	[If the entity complies with paragraph (a):] the fact that we have a committee or committees to oversee risk that comply with paragraphs (1) and (2): in our Corporate Governance Statement OR at this location: Insert location here and a copy of the charter of the committee:	an explanation why that is so in our Corporate Governance Statement

Corpo	orate Governance Council recommendation	We have followed the recommendation in full for the whole of the period above. We have disclosed	We have <u>NOT</u> followed the recommendation in full for the whole of the period above. We have disclosed
	 (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; OR (b) if it does not have a risk committee or committees that satisfy (a) above, disclose that fact and the processes it employs for overseeing the entity's risk management framework. 	at this location: Insert location here and the information referred to in paragraphs (4) and (5): in our Corporate Governance Statement OR at this location: Insert location here [If the entity complies with paragraph (b):] the fact that we do not have a risk committee or committees that satisfy (a) and the processes we employ for overseeing our risk management framework: in our Corporate Governance Statement OR at this location:	
7.2	The board or a committee of the board should: (a) review the entity's risk management framework at least annually to satisfy itself that it continues to be sound; and (b) disclose, in relation to each reporting period, whether such a review has taken place.	the fact that we follow this recommendation: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement
7.3	A listed entity should disclose: (a) if it has an internal audit function, how the function is structured and what role it performs; OR (b) if it does not have an internal audit function, that fact and the processes it employs for evaluating and continually improving the effectiveness of its risk management and internal control processes.	[If the entity complies with paragraph (a):] how our internal audit function is structured and what role it performs: in our Corporate Governance Statement OR at this location: Insert location here [If the entity complies with paragraph (b):] the fact that we do not have an internal audit function and the processes we employ for evaluating and continually	an explanation why that is so in our Corporate Governance Statement

Corpo	rate Governance Council recommendation	We have followed the recommendation in full for the whole of the period above. We have disclosed	We have <u>NOT</u> followed the recommendation in full for the whole of the period above. We have disclosed
		improving the effectiveness of our risk management and internal control processes: ✓ in our Corporate Governance Statement OR at this location: Insert location here	
7.4	A listed entity should disclose whether it has any material exposure to economic, environmental and social sustainability risks and, if it does, how it manages or intends to manage those risks.	whether we have any material exposure to economic, environmental and social sustainability risks and, if we do, how we manage or intend to manage those risks: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement
PRIN	CIPLE 8 – REMUNERATE FAIRLY AND RESPONSIBI	<u>LY</u>	
8.1	The board of a listed entity should: (a) have a remuneration committee which: (1) has at least three members, a majority of whom are independent directors; and (2) is chaired by an independent director, and disclose: (3) the charter of the committee; (4) the members of the committee; and (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; OR (b) if it does not have a remuneration committee, disclose that fact and the processes it employs for setting the level and composition of remuneration for directors and senior executives and ensuring that such remuneration is appropriate and not excessive.	[If the entity complies with paragraph (a):] the fact that we have a remuneration committee that complies with paragraphs (1) and (2): performs: □ in our Corporate Governance Statement OR □ at this location: Insert location here and a copy of the charter of the committee: □ at this location: http://www.medibio.com.au/index.php/about/corporate-governance Insert location here and the information referred to in paragraphs (4) and (5): □ in our Corporate Governance Statement OR □ at this location:	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable

Corporate Governance Council recommendation		We have followed the recommendation in full for the whole of the period above. We have disclosed	We have <u>NOT</u> followed the recommendation in full for the whole of the period above. We have disclosed
8.2	A listed entity should separately disclose its policies and practices regarding the remuneration of non-executive directors and the remuneration of executive directors and other senior executives.	Insert location here [If the entity complies with paragraph (b):] the fact that we do not have a remuneration committee and the processes we employ for setting the level and composition of remuneration for directors and senior executives and ensuring that such remuneration is appropriate and not excessive: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable
8.3	A listed entity which has an equity-based remuneration scheme should: (a) have a policy on whether participants are permitted to enter into transactions (whether through the use of derivatives or otherwise) which limit the economic risk of participating in the scheme; and	Insert location here our policy on this issue or a summary of it: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement OR we do not have an equity-based remuneration scheme and this recommendation is therefore not applicable OR we are an externally managed entity and this

Corporate Governance Council recommendation		We have followed the recommendation in full for the whole of the period above. We have disclosed	We have \underline{NOT} followed the recommendation in full for the whole of the period above. We have disclosed
ADDI	TIONAL DISCLOSURES APPLICABLE TO EXTERNA	LLY MANAGED LISTED ENTITIES	
-	Alternative to Recommendation 1.1 for externally managed listed entities: The responsible entity of an externally managed listed entity should disclose: (a) the arrangements between the responsible entity and the listed entity for managing the affairs of the listed entity; (b) the role and responsibility of the board of the responsible entity for overseeing those arrangements.	the information referred to in paragraphs (a) and (b): in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement
-	Alternative to Recommendations 8.1, 8.2 and 8.3 for externally managed listed entities: An externally managed listed entity should clearly disclose the terms governing the remuneration of the manager.	the terms governing our remuneration as manager of the entity: in our Corporate Governance Statement OR at this location: Insert location here	an explanation why that is so in our Corporate Governance Statement

Corporate Governance Statement

This document discloses the extent to which Medibio Limited ABN 58 008 130 336 ('Medibio' or 'Company') has followed the recommendations set by the ASX Corporate Governance Council in the third edition of its Corporate Governance Principles and Recommendations (ASX Recommendations) during the relevant part of the reporting period.

This document is current as at 30 June 2016 and has been approved by the board of the Company.

PRINCIPLES AND RECOMMENDATIONS	COMPLY	EXPLANATION
	(YES/NO)	

Principle 1: Lay solid foundations for management and oversight

Recommendation 1.1		
A listed entity should disclose:		Refer Section 3 of the Company's Primary Board Charter for further
(a) the respective roles and responsibilities of its board and	Yes	detail which is located on the Company's website at the following link:
management; and		http://www.medibio.com.au/corporate-governance/
(b) b) those matters expressly reserved to the board and those delegated	Yes	
to management.		
Recommendation 1.2		
A listed entity should:		
a) undertake appropriate checks before appointing a person, or putting	Yes	Refer to the Company's Primary Board Charter for further detail which
forward to security holders a candidate for election, as a director; and		is located on the Company's website at the following link:
		http://www.medibio.com.au/corporate-governance/
b) provide security holders with all material information relevant to a	Yes	Information is included in The Company's Notice of Meetings to
decision on whether or not to elect or re-elect a director.		shareholders.
Recommendation 1.3		
A listed entity should have a written agreement with each director and senior	Yes	Refer Section 3 of the Company's Primary Board Charter for further
executive setting out the terms of their appointment.		detail which is located on the Company's website at the following link:
		http://www.medibio.com.au/corporate-governance/
		Details of executive contracts in place are detailed in the Company's
		Annual Remuneration Report in the 2016 Annual Report

Principle 1: Lay solid foundations for management and oversight

Recom	nmendatio	on 1.5					
A listed	d entity sh	nould:					
,		Yes	Refer to Section 2				
		et measurable objectives for achieving gender diversity; and		which is located or			-
		issess annually both the objectives and the entity's progress eving them;		http://www.medibio.com.au/corporate-governance/			
(b) disclose that policy or a summary or it; and		No	Due to the current size and composition of the organisation the Board does not consider it appropriate to provide measurable objectives in relation to gender. The Company is committed to ensuring that the appropriate mix of skills, experience, expertise and diversity are considered when employing staff at all levels of the organisation and when making new senior executive and Board appointments and is satisfied that the composition of employees, senior executives and members of the Board is appropriate.				
	(ii) eith	ner:		inclibers of the bo		ic.	
	(A)	the respective proportions of men and women on the board, in senior executive positions and across the whole organisation (including how the entity has defined "senior executive" for these purposes); or	No	The proportion of positions and wom reporting date was	nen employees i		
						Senior	Whole
	(B)	the entity's "Gender Equality Indicators", as defined in	Not			executive	organisation
		the Workplace Gender Equality Act 2012.	Applicable	Gender	Board	positions	
				No of women	0	0	0
				% women	0%	0%	0%
A listed	mendation	nould:	Vac	Refer Section 3 of		•	
(a)		d disclose a process for periodically evaluating the	Yes	which is located or http://www.medib			-
	and	ance of the board, its committees and individual directors;		The Company did of financial year.			
(b)		in relation to each reporting period, whether a ance evaluation was undertaken in the reporting period in	Yes	, , , , , , , , , , , , , , , , , , , ,			

PRINCIPLES AND RECOMMENDATIONS	COMPLY	EXPLANATION
	(YES/NO)	

accordance with that process.		
Recommendation 1.7		
A listed entity should:	Yes	Refer Section 3 of the Company's Primary Board Charter for further detail
(a) have and disclose a process for periodically evaluating the		which is located on the Company's website at the following link:
performance of its senior executives; and	Yes	http://www.medibio.com.au/corporate-governance/
(b) disclose in relation to each reporting period, whether a		
performance evaluation was undertaken in the reporting period in		Performance evaluations were undertaken in the 2016 financial year
accordance with that process.		

Principle 2: Structure the board to add value

Recommendation 2.1		
The board of a listed entity should:		The Board has no established a Nomination & Remuneration
(a) have a nomination committee which:	(a) No	Committee to assist the Board in ensuring it is equipped to discharge
(i) has at least three members, a majority of whom are independent directors; and	(i) N/A	its responsibilities. The Committee has guidelines for the nomination and selection of directors and for the operation of the Board. Whilst
(ii) is chaired by an independent director,	(ii) N/A	the Committee has been formed, given the size and nature of the
and disclose:		Company's operations to date the Board has chosen to discuss those
(iii) the charter of the committee;	(iii)N/A	matters usually considered by the Nomination & Remuneration
(iv) the members of the committee; and (v) as at the end of each	(iv)N/A	Committee on a regular basis at the full Board during its regular
reporting period, the number of times the committee met throughout	(v) N/A	meetings.
the period and the individual attendances of the members at those		The Board Comprises of:
meetings; or		Chris Indermaur – Independent Chairman
(b) if it does not have a nomination committee, disclose that fact and the	(b)N/A	James Campbell – Independent Member
processes it employs to address board succession issues and to ensure		Frank Prendergast – independent Member
that the board has the appropriate balance of skills, experience, independence and knowledge of the entity to enable it to discharge its		Kris Knauer – non-independent member
duties and responsibilities effectively.		Refer to the Company's Nomination and Remuneration Committee
		Charter which is located on the Company's website at the following
		link: http://www.medibio.com.au/asx-announcement/
		Refer to the Company's 2016 Annual Report which is located on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/

	(YES/NO)	
Recommendation 2.2 A listed entity should have and disclose a board skill matrix setting out the mix of skills and diversity that the board currently has or is looking to achieve in its membership.		Refer Section 3 of the Company's Board Charter for further detail which is located on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/
Recommendation 2.3 A listed entity should disclose: (a) the names of the directors considered by the board to be independent directors; (b) if a director has an interest, position, association or relationship of the type described in Box 2.3 of the ASX Corporate Governance Principles and Recommendation (3rd Edition), but the board is of the opinion that it does not compromise the independence of the director, the nature of the interest, position, association or relationship in question and an explanation of why the board is of that opinion; and (c) the length of service of each director.	Yes Yes	The Board consists of four Directors, three of which (being Chris Indermaur, James Campbell and Frank Prendergast) are considered independent. The Board considers independence having regard to the indicia in Box 2.3 in the ASX Recommendations. The Board has considered the holdings of shares in the Company by each independent director and is of the opinion that their respective interests in shares would not materially interfere with, or could be reasonably perceived to interfere with, the independent exercise of their judgement in their position as a Director. The Board also considers that Chris Indermaur, James Campbell and Frank Prendergast are otherwise free from any business or other relationship that could materially interfere with, or reasonably be perceived to interfere with, the independent exercise of their judgement, and that each of these Directors is able to fulfil the role of independent Director for the purposes of the ASX Recommendations. The other Director – Kris Knauer is considered by the Board to not be independent on the basis that he is engaged in an executive management roles and has substantial shareholdings in the Company The lengths of service are as follows: • Chris Indermaur – Independent Chairman (1.5 years) • James Campbell – Independent Member (2 years) • Frank Prendergast – independent Member (0.6 years)

COMPLY EXPLANATION

PRINCIPLES AND RECOMMENDATIONS

PRINCIPLES AND RECOMMENDATIONS	COMPLY (YES/NO)	EXPLANATION
Recommendation 2.4 A majority of the board of a listed entity should be independent directors.	Yes	As noted above in Recommendation 2.3, the Board is composed of three independent directors and one non-independent directors.
Recommendation 2.5 The chair of the board of a listed entity should be an independent director and, in particular, should not be the same person as the CEO of the entity.	Yes	The Chairman, Chris Indermaur is an independent director. The roles of Chairman and Chief Executive Officer are exercised by different individuals, being Chris Indermaur and Kris Knauer respectively.
Recommendation 2.6 A listed entity should have a program for inducting new directors and providing appropriate professional development opportunities for continuing directors to develop and maintain the skills and knowledge needed to perform their role as a director effectively.	Yes	The Nomination & Remuneration Committee oversees, reviews and makes recommendations to the Board in relation to the induction, training and development of Non-Executive Directors, to ensure they have access to appropriate learning and development opportunities to develop and maintain the skills and knowledge required to effectively perform in their role as a Director. The Board receives regular updates at board meetings which assist directors in keeping up to date with relevant market and industry developments. There are also procedures in place, agreed by the Board, to enable Directors, in furtherance of their duties, to seek independent professional advice at the Company's expense.

Recommendation 3.1	Yes to	For further detail refer to the Company's Supplementary Policies for
A listed entity should:	all	directors and senior executives which is located on the Company's
(a) have a code of conduct for its directors, senior executives and employees;		website at the following link:
and		http://www.medibio.com.au/corporate-governance/
(b) disclose that code or a summary of it		

Principle 4: Safeguard integrity in financial reporting

Recommendation 4.1		
The board of a listed entity should:		It is the Board's responsibility to ensure that an effective internal
(a) have an audit committee which:	Yes	control framework exists within the entity. This includes internal
(i) has at least three members, all of whom are non-executive directors	Yes	controls to deal with both the effectiveness and efficiency of significant
and a majority of whom are independent directors; and		business processes, the safeguarding of assets, the maintenance of
(ii) is chaired by an independent director, who is not the chair of the	Yes	proper accounting records, and the reliability of financial information

PRINCIPLES AND RECOMMINENDATIONS	(YES/NO)	EXPLANATION
board, and disclose: (iii) the charter of the committee; (iv) the relevant qualifications and experience of the members of the committee; and (v) in relation to each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have an audit committee, disclose that fact and the processes it employs that independently verify and safeguard the integrity of its financial reporting, including the processes for the appointment and removal of the external auditor and the rotation of the audit engagement partner.	Yes Yes N/A	as well as non-financial considerations such as the benchmarking of operational key performance indicators. The Board has established an Audit & Risk Committee, which operates under a formal charter approved by the Board, to which it has delegated the responsibility to establish and maintain the framework of internal control and ethical standards for the management of the company. The Committee also provides the Board with additional assurance regarding the reliability of financial information for inclusion in the financial reports. At the date of this report the Committee comprises of three members, the majority of whom are independent Directors and the Chair of the Committee is not the Chair of the Board as follows: • James Campbell – Independent Chairman • Chris Indermaur – Independent Member • Frank Prendergast – independent Member Refer Company's Audit Committee Charter which is located on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/ For further information refer to the Company's Annual Report which is located on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/
Recommendation 4.2 The board of a listed entity should, before it approves the entity's financial statements for a financial period, receive from its CEO and CFO a declaration that the financial records of the entity have been properly maintained and that the financial statements comply with the appropriate accounting standards and give a true and fair view of the financial position and performance of the entity and that the opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.	Yes	The CEO and Company Secretary execute Section 295A declarations and submit to the Audit Committee and Board prior to approving the Annual Report.

COMPLY EXPLANATION

PRINCIPLES AND RECOMMENDATIONS

	(TES/NO)	
Recommendation 4.3		
A listed entity that has an AGM should ensure that its external auditor	Yes	The Auditor attends the Company Annual General Meeting
attends its AGM and is available to answer questions from security holders		
relevant to the audit.		

COMPLY EXPLANATION

Principle 5: Make timely and balanced disclosure

PRINCIPLES AND RECOMMENDATIONS

Recommendation 5.1		
A listed entity should:	Yes	Refer Section 3 of the Company's Continuous Disclosure Policy and
(a) have a written policy for complying with its continuous disclosure		Procedures for further detail which is located on the Company's
obligations under the Listing Rules; and	Yes	website at the following link:
(b) disclose that policy or a summary of it.		http://www.medibio.com.au/corporate-governance/

Principle 6: Respect the rights of security holders

Recommendation 6.1 A listed entity should provide information about itself and its governance to investors via its website.	Yes	Refer Section 2 of the Company's Investor Policy for further detail which is located on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/
Recommendation 6.2 A listed entity should design and implement an investor relations program to facilitate effective two-way communication with investors.	Yes	Refer Section 2 of the Company's Investor Policy for further detail which is located on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/
Recommendation 6.3 A listed entity should disclose the policies and processes it has in place to facilitate and encourage participation at meetings of security holders.	Yes	Refer Section 3 of the Company's Investor Policy for further detail which is located on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/
Recommendation 6.4 A listed entity should give security holders the option to receive communications from, and send communications to, the entity and its security registry electronically.	Yes	Refer Section 3 of the Company's Investor Relations Policies for further detail which is located on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/

Principle 7: Recognise and manage risk

Recommendation 7.1		
The board of a listed entity should:		
 (a) have a committee or committees to oversee risk, each of which: (i) has at least three members, a majority of whom are independent directors; and (ii) is chaired by an independent director, and disclose: (iii) the charter of the committee; (iv) the members of the committee; and (v) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have a risk committee or committees that satisfy (a) above, 	(a) No (i) N/A (ii) N/A (iii) N/A (iv) N/A (v) N/A (b) Yes	, ,
disclose that fact and the process it employs for overseeing the entity's risk management framework.		
Recommendation 7.2 The board or a committee of the board should: (a) review the entity's risk management framework with management at least annually to satisfy itself that it continues to be sound, to determine whether there have been any changes in the material business risks the entity faces and to ensure that they remain within the risk appetite set by the board; and (b) disclose in relation to each reporting period, whether such a review has taken place.	Yes to all	Management, through the Managing Director and Chief Executive Officer, is responsible for designing, implementing and reporting on the adequacy of the Company's risk management and internal control system. Management reports to the Audit Committee on the Company's key risks and the extent to which it believes these risks are being monitored at each Committee meeting. The Audit Committee review and monitor management's risk management and internal compliance and control systems.
		On a continuous basis the Board has charged the Committee with responsibility that: • clearly describe the respective roles of the Board, the Committee and Management; and • prescribe the necessary elements of an effective risk management system, namely, oversight, risk profile, risk management, compliance and control, and assessment of system effectiveness.

PRINCIPLES AND RECOMMENDATIONS	COMPLY (YES/NO)	EXPLANATION
		Refer to the Company's Audit Committee Charter which is located on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/
Recommendation 7.3 A listed entity should disclose: (a) if it has an internal audit function, how the function is structured and what role it performs; or (b) if it does not have an internal audit function, that fact and the processes it employs for evaluating and continually improving the effectiveness of its risk management and internal control processes.	a) N/A b) Yes	Given the size of the company, there is no internal audit function. Detailed risk assessments are carried out in respect of a wide range of items, and where appropriate and possible, risk mitigation strategies are implemented to minimise the chance of the risks occurring, and to minimise any impact where a risk eventuates. The Managing Director and Chief Executive Officer and Chief Financial Officer provide written confirmation to the Board in accordance with the requirements of Section 295A (2) of the Corporations Act 2001. This certification is founded on a sound system of risk management and internal compliance and control, which implement the policies adopted by the Board and the Company's risk management and internal compliance and control systems are operating efficiently and effectively in all material respects. Refer to the Company's Audit & Risk Committee Charter which is located on the Company's website at the following link: http://www.medibio.com.au/corporate-governance/
Recommendation 7.4 A listed entity should disclose whether, and if so how, it has regard to economic, environmental and social sustainability risks and, if it does, how it manages or intends to manage those risks.	No	The Board does not consider that the Company has any material environmental of social sustainability risks or exposures.

PRINCIPLES AND RECOMMENDATIONS	COMPLY	EXPLANATION
	(YES/NO)	
Recommendation 8.1		
The board of a listed entity should:		The Board does not have a Nomination & Remuneration Committee
a) have a remuneration committee which:	(a) No	due to the smallness of the Board – 4 members. The duties are
(i) has at least three members, a majority of whom are independent directors; and	(i) N/A	discharged by the full Board with any conflicted member removing themselves from the meeting.
(ii) is chaired by an independent director, and disclose:	(ii) N/A	
(iii) the charter of the committee;	(iii) N/A	Refer to the Company's Charter which is located on the Company's
(iv) the members of the committee; and	(iv) N/A	website at the following link:
 (v) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or 	(v) N/A	http://www.medibio.com.au/corporate-governance/
b) if it does not have a remuneration committee, disclose that fact and the processes it employs for setting the level and composition of	(b) N/A	Refer to the Company's 2016 Annual Report which is located on the Company's website at the following link:
remuneration for directors and senior executives and ensuring that such remuneration is appropriate and not excessive.		http://www.medibio.com.au/corporate-governance/
Recommendation 8.2		
A listed entity should separately disclose its policies and practices regarding the remuneration of non-executive directors and the remuneration of executive directors and other senior executives.	Yes	Separate disclosure regarding the remuneration of the Company's directors (executive and non-executive) and CEO is disclosed in the Company's Annual report, as lodged with the ASX and issued to shareholders.
		A copy of the latest Annual Report containing this disclosure can be

Yes

Recommendation 8.3

A listed entity which has an equity-based remuneration scheme should:

- (a) have a policy on whether participants are permitted to enter into transactions (whether through the use of derivatives or otherwise) which limit the economic risk of participating in the scheme; and
- (b) disclose that policy or a summary of it.

A copy of the latest Annual Report containing this disclosure can be

accessed at

http://www.medibio.com.au/corporate-governance/

The Company does not have an equity based remuneration scheme in place.

Details of remuneration this are outlined in the Company 2016 Annual Report.